Inhibition of MAN2A1 Enhances the Immune Response to Anti–PD-L1 in Human Tumors

Abstract

<i>Man2a1</i> loss renders cancer cells more susceptible to T-cell-mediated killing. Swainsonine synergizes with anti-PD-L1 in suppressing tumor growth. In light of the limited efficacy of anti-PD-L1 and failed phase II clinical trial on swainsonine, our study reveals a potential therapy combining the two to overcome tumor immune evasion.<i>See related commentary by Bhat and Kabelitz, p. 5778</i>.